Combined fertility treatment available

Merck Serono has launched Pergoveris (follitropin alfa/lutropin alfa), indicated for the stimulation of follicular development in women with severe lutinising hormone (LH) and follicle stimulating hormone (FSH) deficiency.

Treatment with Pergoveris should be initiated under the supervision of a physician experienced in the treatment of fertility problems and given as a course of daily injections.


Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and oestrogen response. A recommended regimen commences with one vial of Pergoveris daily.

Further information: Merck Serono 020 8818 7200

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Added: glycopyrronium bromide, Sytron and tolterodine.

Free on MIMS Learning: coronavirus resources

Free on MIMS Learning: coronavirus resources

Free learning resources for healthcare professionals...

COVID-19 outbreak: continue ARBs and ACE inhibitors, GPs urged

COVID-19 outbreak: continue ARBs and ACE inhibitors, GPs urged

Prescribers should not stop angiotensin receptor blockers...